Last reviewed · How we verify
CAM-101 30%
At a glance
| Generic name | CAM-101 30% |
|---|---|
| Also known as | FD hPL 30% vol/vol |
| Sponsor | Cambium Bio Limited |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Topical Fibrinogen-Depleted Human Platelet Lysate in Patients With Dry Eye Secondary to Graft vs. Host Disease (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CAM-101 30% CI brief — competitive landscape report
- CAM-101 30% updates RSS · CI watch RSS
- Cambium Bio Limited portfolio CI